179 related articles for article (PubMed ID: 12853342)
21. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Howell A
Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
[TBL] [Abstract][Full Text] [Related]
22. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
23. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Buzdar AU
Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
[TBL] [Abstract][Full Text] [Related]
24. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Croxtall JD; McKeage K
Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
[TBL] [Abstract][Full Text] [Related]
25. Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Lynn J
Eur J Oncol Nurs; 2004; 8 Suppl 2():S83-8. PubMed ID: 15590319
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen--what next?
Gradishar WJ
Oncologist; 2004; 9(4):378-84. PubMed ID: 15266091
[TBL] [Abstract][Full Text] [Related]
27. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
28. A new estrogen receptor antagonist--an overview of available data.
Jones SE
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
[TBL] [Abstract][Full Text] [Related]
29. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
Parker LM
Clin Ther; 2002; 24 Suppl C():C43-57. PubMed ID: 12117075
[TBL] [Abstract][Full Text] [Related]
30. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
31. Life following aromatase inhibitors--where now for endocrine sequencing?
Johnston SR; Martin LA; Dowsett M
Breast Cancer Res Treat; 2005; 93 Suppl 1():S19-25. PubMed ID: 16247596
[TBL] [Abstract][Full Text] [Related]
32. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Telford C; Jones N; Livings C; Batson S
Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
[TBL] [Abstract][Full Text] [Related]
33. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
34. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Dodwell D; Wardley A; Johnston S
Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
[TBL] [Abstract][Full Text] [Related]
35. Existing and emerging endocrine therapies for breast cancer.
Dow KH
Cancer Nurs; 2002 Apr; 25 Suppl 2():6S-11S. PubMed ID: 12080538
[TBL] [Abstract][Full Text] [Related]
36. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
37. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
38. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Murray R
Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
[TBL] [Abstract][Full Text] [Related]
39. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]